


WHAT IS CLAIMED IS:

1. A compound of the following Formula (I)



wherein,

R^1 is hydrogen, COR^a , or $COOR^a$;

each of R^2 , R^3 and R^4 is, independently, hydrogen, C_1 - C_{10} alkyl, or OR^b , with the proviso that R^2 , R^3 and R^4 cannot all be hydrogen;

each of R^5 and R^6 is, independently, hydrogen, C_1 - C_6 alkyl, OR^c , nitro, halo, $N(R^c)_2$, $NH(CH_2)_pN(R^c)_2$, $(CH_2)_qOH$, $(CH_2)_qX$, $CONHR^c$, $CONH(CH_2)_pN(R^c)_2$, SO_3R^c , or SO_2R^c with the proviso that when R^1 is hydrogen and R^4 is CH_3 , R^5 and R^6 cannot both be hydrogen; and

each of m and n , is independently, 0-4;

in which R^a is aryl, or C_1 - C_{10} alkyl, optionally substituted with oxo; R^b is C_1 - C_{10} alkyl; R^c is hydrogen or C_1 - C_{10} alkyl; p is 1-5; and q is 1-3.

2. The compound of claim 1, wherein one of R^2 , R^3 and R^4 is C_1 - C_6 alkyl or OR^b and one of R^2 , R^3 and R^4 is hydrogen.
3. The compound of claim 2, wherein R^1 is hydrogen.
4. The compound of claim 2, wherein R^1 is COR^a or $COOR^a$.

- 24 5. The compound of claim 4, wherein R^a is C_1 - C_4 alkyl, optionally substituted with oxo.
25
- 26 6. The compound of claim 2, wherein each of R^5 and R^6 is independently, hydrogen, C_1 - C_6
27 alkyl, OR^c or $CONHR^c$, or $CONH(CH_2)_pN(R^c)_2$, and each of m and n is, independently, 1.
28
- 29 7. The compound of claim 6, wherein R^c is C_1 - C_4 alkyl and p is 2.
30
- 31 8. The compound of claim 2, wherein one of R^2 , R^3 and R^4 is C_1 - C_4 alkyl or OR^b , R^b being
32 C_1 - C_4 alkyl.
33
- 34 9. The compound of claim 8, wherein R^1 is COR^a or $COOR^a$, R^a being C_1 - C_4 alkyl,
35 optionally substituted with oxo.
36
- 37 10. The compound of claim 8, wherein R^1 is H.
38
- 39 11. The compound of claim 8, wherein R^5 and R^6 are each independently hydrogen, C_1 - C_6
40 alkyl, OR^c or $CONHR^c$, or $CONH(CH_2)_pN(R^c)_2$; and each of m and n is, independently,
41 1.
42
- 43 12. The compound of claim 11, wherein R^c is C_1 - C_4 alkyl and p is 2.
44
- 45 13. The compound of claim 2, wherein one of R^2 , R^3 and R^4 is CH_3 or OCH_3 .
46
- 47 14. The compound of claim 13, wherein R^1 is COR^a or $COOR^a$.
48
- 49 15. The compound of claim 14, wherein R^a is C_1 - C_4 alkyl, optionally substituted with oxo.
50
- 51 16. The compound of claim 15, wherein R^1 is $COCH_2CH_2COCH_3$ or $COOCH_2CH_3$.
52

- 53 17. The compound of claim 16, wherein R^5 and R^6 are each independently hydrogen, C_1 - C_6
54 alkyl, OR^c , $CONHR^c$, or $CONH(CH_2)_pN(R^c)_2$; and each of m and n is, independently, 1.
55
- 56 18. The compound of claim 17, wherein R^c is C_1 - C_4 alkyl and p is 2.
57
- 58 19. The compound of claim 18, wherein R^5 is $CONH(CH_2)_2N(CH_3)_2$ and R^6 is CH_3 .
59
- 60 20. The compound of claim 19, wherein R^5 and R^6 are at the C-4 and C-5 positions of the
61 acridine ring, respectively.
62
- 63 21. The compound of claim 20, wherein the compound is {3-[4-(2-dimethylamino-
64 ethylcarbamoyl)-5-methyl-acridin-9-ylamino]-5-methyl-phenyl}-carbamic acid ethyl
65 ester, or {3-[4-(2-dimethylamino-ethylcarbamoyl)-5-methyl-acridin-9-ylamino]-4-
66 methyl-phenyl}-carbamic acid ethyl ester.
67
- 68 22. The compound of claim 13, wherein R^1 is hydrogen.
69
- 70 23. The compound of claim 22, wherein R^5 and R^6 are each independently hydrogen, C_1 - C_6
71 alkyl, OR^c , $CONHR^c$, or $CONH(CH_2)_pN(R^c)_2$, and each of m and n is, independently, 1.
72
- 73 24. The compound of claim 23, wherein R^c is C_1 - C_4 alkyl and p is 2.
74
- 75 25. The compound of claim 24, wherein R^5 is $CONH(CH_2)_2N(CH_3)_2$ and R^6 is CH_3 .
76
- 77 26. The compound of claim 25, wherein R^5 and R^6 are at the C-4 and C-5 positions of the
78 acridine ring, respectively.
79
- 80 27. The compound of claim 26, wherein the compound is [9-(1-amino-5-methyl-
81 phenyl)amino]-5-methyl-acridine-4-carboxylic acid (2-dimethylamino-ethyl)-amide or
82 [9-(5-amino-2-methyl-phenyl)amino]-5-methyl-acridine-4-carboxylic acid (2-

dimethylamino-ethyl)-amide.

28. A pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable salt or carrier.

29. The composition of claim 28, wherein the compound is a compound of claim 7.

30. The composition of claim 28, wherein the compound is a compound of claim 13.


31. The composition of claim 28, wherein the compound is a compound of claim 21.

32. The composition of claim 28, wherein the compound is a compound of claim 27.


33. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of the compound of Formula (I).

34. The method of claim 33, wherein the cancer is colon cancer, stomach cancer, brain cancer, breast cancer, or leukemia.


35. A method for synthesizing a compound of Formula (II):



the method comprising: contacting a compound of Formula (III):



with a compound of Formula (IV):



to form a compound of Formula (IV), wherein:

R^4 is C_1 - C_{10} alkyl or OR^b ;

each of R^5 and R^6 is, independently, hydrogen, C_1 - C_6 alkyl, OR^c , nitro, halo, $N(R^c)_2$, $NH(CH_2)_pN(R^c)_2$, $(CH_2)_qOH$, $(CH_2)_qX$, $CONHR^c$, $CONH(CH_2)_pN(R^c)_2$, SO_3R^c , or SO_2R^c ; and

each of m and n , is independently, 0-4;

in which R^a is aryl, or C_1 - C_{10} alkyl, optionally substituted with oxo; R^b is C_1 - C_{10} alkyl; R^c is hydrogen or C_1 - C_{10} alkyl; p is 1-5; q is 1-3;

L is halo, OSO_2R^7 , or OR^7 ; and

R^7 is alkyl, haloalkyl, or aryl optionally substituted with halo or nitro.